NTRB - Nutriband Inc

https://www.nutriband.com

Recent News

Nutriband Inc. ( NTRB ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 5 days, 17 hours ago • score: 0.11

Nutriband (NTRB) delivered earnings and revenue surprises of -1,147.06% and -11.77%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.

52W High

$11.78

52W Low

$3.72

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.29

Valuation

Rich

As of 2025-04-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

370.37

EV/EBITDA (<8 favorable)

-4.56

EV/Revenue (<3 favorable)

30.61

P/S (TTM) (<3 favorable)

31.73

P/B (<3 favorable)

14.91

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

76.37%

Institutions (25–75% balanced)

3.12%

Shares Outstanding

11,928,500

Float

3,097,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-04-30 (Overview)

Revenue (TTM)

2,398,400

Gross Profit (TTM)

830,510

EPS (TTM)

-0.90

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-2.12%

ROE (TTM) (>15% strong)

-1.08%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.63

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—